EMA planning new guidance to address "multiplicity issues" in drug clinical trials
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking feedback on its proposal to develop new guidance on multiplicity issues in drug trials1. Multiplicity issues, if not handled properly, can present an elevated probability of "false positives" when performing multiple analyses and hence result in unsubstantiated effectiveness claims for the drug.
You may also be interested in...
EMA Can Do More With Its Guidance On Multiplicity Issues In Clinical Trials, Says EFPIA
EU research-based industry association EFPIA has made several suggestions to improve the European Medicines Agency’s draft guideline on addressing multiplicity issues in clinical trials. Multiplicity can have a substantial influence on the rate of false-positive conclusions, which may affect approval and labeling of an investigational drug.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.